FindTrial
Sign In

Intervention1: Olaparib Tablets 150 mg 150 mg x 2 Twice daily: Multiple oral dose of Olaparib Tablets 150 mg 150 mg x 2 Twice daily will be administered in each period Total Duration of the study is 1

2 trials

Sponsors

BDR pharmaceuticals International Pvt Ltd

Conditions

Health Condition 1: C50- Malignant neoplasm of breast Health Condition 2: C56- Malignant neoplasm of ovary Health Condition 3: C25- Malignant neoplasm of pancreas Health Condition 4: C61- Malignant neoplasm of prostateHealth Condition 1: C50-C50- Malignant neoplasms of breast Health Condition 2: C56- Malignant neoplasm of ovary Health Condition 3: C61- Malignant neoplasm of prostate Health Condition 4: C25- Malignant neoplasm of pancreas

Unknown Phase

Multi centre Multiple Dose Study Comparing Olaparib Tablets 150 mg in Adult Patients with carcinoma of the ovary breast prostate or adenocarcinoma of the pancreas under Fasting Conditions
Active, not recruitingCTRI/2026/07/113680
BDR pharmaceuticals International Pvt LtdHealth Condition 1: C50-C50- Malignant neoplasms of breast Health Condition 2: C56- Malignant neoplasm of ovary Health Condition 3: C61- Malignant neoplasm of prostate Health Condition 4: C25- Malignant neoplasm of pancreas
Target: 42Updated: 2026-08-03
Multiple Dose Study Comparing Olaparib Tablets 150 mg in Adult Patients with carcinoma of the ovary breast prostate or adenocarcinoma of the pancreas under Fed Conditions
Active, not recruitingCTRI/2026/07/113709
BDR pharmaceuticals International Pvt LtdHealth Condition 1: C50- Malignant neoplasm of breast Health Condition 2: C56- Malignant neoplasm of ovary Health Condition 3: C25- Malignant neoplasm of pancreas Health Condition 4: C61- Malignant neoplasm of prostate
Target: 42Updated: 2026-08-03